SecBot SecBot
Biotech Drug Report Generated Jul 13, 2026

sevasemten

EWTX·Edgewise Therapeutics, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 2/3 (pivotal) for Becker muscular dystrophy; Phase 2 for Duchenne muscular dystrophy
Time to market
Potential FDA approval target end-2027 for Becker muscular dystrophy (if GRAND CANYON positive, NDA submission H1 2027). Duchenne program is earlier-stage (Phase 2).
Why 4/10
The next hard, dated catalyst is the GRAND CANYON pivotal topline readout in Q4 2026 (~3-5 months away). However, the drug was sold to Servier in a deal that closed July 13, 2026, with $1.55B upfront already banked by Edgewise. The readout determines up to $1.1B in milestone payments but is not existential for EWTX, which is now pivoting to a cardiovascular pipeline. ImpactScore 4: meaningful milestone catalyst but no longer the company's defining binary.
Actionable Insight NEUTRAL

Sevasemten is no longer Edgewise's asset, it was sold to Servier. For EWTX holders, watch the GRAND CANYON readout (Q4 2026) which triggers up to $1.1B in milestone payments, but the stock's primary thesis now rests on the cardiovascular pipeline (EDG-7500). For non-EWTX investors, sevasemten's fate is in Servier's hands; there's no pure-play public stock directly tied to this drug.

Price Chart

Loading chart...

Executive Summary

Sevasemten (EDG-5506) is an oral, first-in-class fast skeletal myosin inhibitor being developed for Becker and Duchenne muscular dystrophies, rare, progressive muscle-wasting diseases with no approved treatments for Becker. The Phase 2 CANYON trial met its primary endpoint, showing a 28% reduction in key muscle damage biomarkers and functional stabilization. On June 1, 2026, Edgewise sold sevasemten and its entire muscular dystrophy business to French pharma Servier for $1.55B upfront plus up to $1.1B in milestones (deal closed July 13, 2026). The pivotal GRAND CANYON study (175 patients, >98% powered) is fully enrolled with top-line results due Q4 2026. If positive, an NDA is planned for H1 2027 with potential approval by end-2027. For Edgewise (EWTX) investors, the $1.55B cash is already locked in; the stock now trades as a cardiovascular-focused company.

How It Works

Sevasemten is a pill that slows muscle damage in people with muscular dystrophy. It works by inhibiting a protein (fast skeletal myosin) that controls forceful muscle contractions, the kind that cause the most damage in fragile, dystrophic muscle. By dampening this contraction-driven injury, the drug aims to preserve muscle function and slow disease progression.

Trial Status

The GRAND CANYON pivotal cohort (Becker) is fully enrolled with 175 participants and >98% powered. Top-line results expected Q4 2026. U.S. NDA planned H1 2027 if positive. The Phase 2 CANYON study previously met its primary endpoint (28% reduction in TNNI2 muscle damage biomarker). Phase 2 Duchenne trials (LYNX, FOX) are ongoing with Phase 3 planning underway. The FDA declined accelerated approval based on Phase 2 data alone, requiring the pivotal GRAND CANYON data.

The Two-Sided Case

▲ Bull Case6
First and only approved therapy specifically for Becker muscular dystrophy if successful (no approved treatments currently exist), CureDuchenne.
Deal with Servier values the program at up to $2.65B, with $1.55B upfront cash already collected by Edgewise, strongly validates the science and derisks financing.
Phase 2 CANYON data showed 28% reduction in TNNI2 muscle damage biomarker and functional stabilization over 1 year, meeting its primary endpoint.
GRAND CANYON study is >98% powered to detect a clinically meaningful 1.8-point improvement, dramatically increasing the probability of a positive result.
FDA Fast Track designation for Duchenne, Orphan Drug Designations (FDA & EMA) for both Becker and Duchenne, and Rare Pediatric Disease designation provide regulatory incentives and expedited review path.
Servier, a global pharma with rare disease commercial infrastructure, will drive late-stage development and regulatory filings going forward.
▼ Bear Case6
The FDA previously declined accelerated approval for sevasemten in Becker, finding the Phase 2 data 'insufficient', meaning the bar for the GRAND CANYON data is high.
Edgewise has sold the drug, for EWTX holders, sevasemten is no longer the company's core asset. The $1.55B upfront is banked, but the stock's future thesis now rests on the early-stage cardiovascular pipeline (EDG-7500), not sevasemten.
Only $1.1B of the $2.65B deal value is contingent on regulatory and commercial milestones, if GRAND CANYON misses, those milestones vanish.
Duchenne program is earlier-stage (Phase 2) with a 25% probability of success per analyst estimates (Fierce Biotech), and faces competition from Sarepta's approved exon-skipping therapies and gene therapies.
Becker is a small rare disease market, commercial upside may be modest even with approval, capping milestone upside.
Key insider sold $5.1M+ worth of stock on July 1, 2026 (CSO Alan Russell via 10b5-1 plan at ~$39/share), near the stock's highs.

Upcoming Catalysts

  • GRAND CANYON pivotal topline results, Q4 2026 (Becker muscular dystrophy)
  • If positive, NDA submission to FDA, H1 2027
  • Potential FDA approval, target end-2027
  • Phase 2 Duchenne data updates (LYNX, FOX studies)
  • Servier-initiated Phase 3 Duchenne study, recruitment start 2026

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Edgewise Therapeutics, Inc. 8-K EWTX ·Originating report

Sources · 15

Hover a chip for the title
1 prnewswire.com2 statnews.com3 tipranks.com4 edgewisetx.com5 rallies.ai6 stocktitan.net7 parentprojectmd.org8 edgewisetx.com9 fiercebiotech.com10 biospace.com11 clinicaltrials.gov12 linkedin.com13 investing.com14 sec.gov15 sec.gov